of peripheral blood B lymphocytes. In conclusion, there was no relationship between peripheral blood B lymphocytes and disease activity, suggesting that peripheral blood B lymphocytes are not a biomarker of disease activity and therapeutic efficacy in IMN.
Introduction
Idiopathic membranous nephropathy (IMN) is an adult primary glomerular disease. 1 It has been estimated that IMN accounts for 25 -40% of all idiopathic nephrotic syndromes in adults. 2 In China, IMN accounts for 9.89% of primary glomerulonephritis. 1 To date, the aetiology and pathogenesis of IMN remain poorly understood and it has been postulated that an in situ immune complex in the glomerular epithelium mediated by antibodies plays a critical role in the initiation of renal injury. 3 In 1959, a membranous nephropathy rat model was developed by Heymann et al. 4 using kidney homogenate. In this model, autoantibodies induced by the homogenate were produced against podocyte membrane protein *L-S Li deceased. B Wang, K Zuo, Y Wu et al. B lymphocytes unrelated to renal disease activity in IMN (megalin) , and typical membranous nephropathy was induced. 5 Megalin was not found in human podocytes. Thus, controversy regarding the pathogenesis of membranous nephropathy has existed for some time.
Recently, one study 6 demonstrated that the anti-M-type phospholipase A 2 receptor (PLA 2 R) was detected in approximately 70% of patients with IMN and a relationship between antibodies against PLA 2 R and proteinuria was noted, suggesting that an antibodymediated immune response plays a dominant role in the pathogenesis of IMN. 7 Antibodies are secreted by plasma cells that are derived from B lymphocytes, implying that B lymphocytes play an important role in the pathogenesis of IMN. Experiments showed the type 2 helper (Th2) T-cells were the dominant cell type in patients with IMN 8 and that the cytokines secreted by Th2 cells could promote the production of immunoglobulin (Ig) G4 type antibodies by B lymphocytes, 9 resulting in membranous nephropathy.
In another study, immunosuppressants were used to block the occurrence of Heymann nephritis, suggesting that inhibiting Th2 cells was crucial for the interruption of IMN development. 10 In addition, B lymphocytes themselves are directly involved in the pathogenesis of IMN as antigen-presenting cells. 11 It has been found that the CD20 mRNA level in the renal interstitium of IMN patients was markedly higher than in patients with minimal change disease or in those with focal segmental glomerulo sclerosis and the number of infiltrating B lymphocytes was also dramatically increased. 10 Thus, B lymphocytes appear to be closely involved in the pathogenesis of IMN and may serve as a biomarker of disease activity in IMN patients. 12 B lymphocytes may also be a favourable target in the treatment of IMN and, to date, the mouse/human chimeric monoclonal antibody (rituximab) against CD20, a B lymphocyte-specific surface antigen, has been applied in the treatment of IMN. 13 Rituximab can rapidly and specifically remove CD20 + B lymphocytes from the peripheral blood and may be effective in the improvement of proteinuria. 14, 15 It is interesting to note that a significantly decreased number of B lymphocytes, or even B lymphocyte deficiency, has been observed in all patients receiving rituximab, although proteinuria does not improve in a proportion of patients. 16 These findings raise a number of important questions. For example, why is the number of peripheral blood B lymphocytes not directly related to the severity of the proteinuria experienced by IMN patients? What is the role of B lymphocytes in the pathogenesis of IMN? Can the number of peripheral blood B lymphocytes be a biomarker of disease activity? Thus, it is imperative to explore the relationship between the number of B lymphocytes in IMN patients and disease activity, the findings of which may be beneficial for monitoring disease status and providing useful evidence of the efficacy of treatments for IMN. Healthy volunteers were recruited from among family members of patients attending Jingling Hospital and residents of Nanjing, and were assigned to the control group. These subjects did not have a history of immunological diseases or recent infections.
Patients and methods

STUDY PARTICIPANTS
The study protocol was approved by the Ethics Research Committee at Nanjing University School of Medicine and written informed consent was obtained from all participants.
RENAL BIOPSY COLLECTION AND HISTOLOGICAL PREPARATION
Ultrasound-guided percutaneous renal biopsy was performed on all participants, with > 10 renal glomeruli being included in each sample. For light microscopy examination, the renal biopsy tissues were embedded in paraffin, cut into 2-µm sections and then stained with haematoxylin and eosin, Masson's trichrome stain, periodic acid-Schiff stain and periodic acid-Schiffmethenamine silver staining. In order to study the characteristics of IMN and exclude secondary MN, electron microscopy was carried out with a Hitachi H-7500 transmission electron microscope (Hitachi Medical Systems, Tokyo, Japan) and doublestaining with uranium and lead performed according to a standard protocol. 17
BIOCHEMICAL ASSAYS
Urinary protein was determined by the Biuret test, serum creatinine was determined by blood biochemical analysis and urinary N-acetyl-β-D-glucosaminidase (NAG) was determined by use of the synthetic substrate 2-chloro-4-nitrophenyl-N-acetyl-β-D-glucosamin ide (CNP-NAG) using standard protocols. Retinol binding protein (RBP) was determined by an enzyme-linked immunosorbent assay (DEBO Science & Technology Development Co., Shanghai, China) according to the manufacturer's instruction. 
DETECTION OF PERIPHERAL BLOOD LYMPHOCYTES
Instruments and reagents
Detection of CD3 + , CD3 + CD4 + , CD3 + CD8 + and CD20 + cells
A 100-µl sample of ethylenediaminetetraacetic acid (EDTA) anticoagulated blood was added to a tube containing 20 µl of anti-CD3-PC5/CD4-FITC/CD8-PE monoclonal antibodies or FITC-labelled anti-CD20 + monoclonal antibody (20 µl isotype-specific IgG conjugated to either FITC/PE/PC5 or FITC was used as a negative control). The mixture was incubated for 30 min at room temperature followed by treatment with the Q-PREP™ Workstation IMMUNOPREP™ Reagent System for analysis (Beckman Coulter Inc.). The data were analysed with BD FACSDiva™ software, version 2.2 (Becton, Dickinson & Co.). Manual lymphocyte gating was used to calculate the percentages of CD3 + , CD3 + CD4 + , CD3 + CD8 + and CD20 + cells in peripheral blood.
Detection of CD4 + CD25 + Foxp3 + regulatory T-cells
A 100-µl sample of EDTA anticoagulated blood was added to a tube containing 20 µl of FITC-labelled anti-CD4 and PE-labelled anti-CD25 monoclonal antibodies that was then incubated in the dark for 30 min at 4°C to label CD4 + CD25 + T-cells. Haematocytolysis and washing were performed for 45 min in 1 ml fixation/permeabilization buffer. Then, the cells were rinsed and blocked in 1 µl normal mouse serum for 15 min at 4°C followed by incubation with 20 µl antihuman Foxp3 monoclonal antibody labelled with APC (or 20 µl isotype-specific IgG conjugated to PE as a control) for 30 min at 4°C. Subsequently, the cells were rinsed twice and resuspended with 300 µl of 0.5 mM Flow Cytometry Staining Buffer (eBioscience), pH 7.0, for analysis. FACSDiva™ software (Becton, Dickinson & Co.) was used for analysis and the number of CD4 + CD25 + Foxp3 + regulatory T-cells in the peripheral blood was counted.
IMMUNOHISTOCHEMICAL ANALYSIS
Renal biopsy sections were deparaffinized and antigen retrieval was achieved by microwave treatment for 10 min in antigen retrieval solution (0.05 mM EDTA, pH 8.0). Then, the slides were incubated with primary antibody against CD20 (mouse antihuman, clone L26 CD20 antibody, 1:100 dilution; Dako, Glostrup, Denmark) for 2 h at 4°C followed by rinsing with 0.1 M PBS, pH 7.4, for 5 min. Subsequently, the sections were incubated with EnVision™+ System Peroxidase (Dako, Glostrup, Denmark) for 30 min followed by washing with 0.1 M PBS, pH 7.4, for 5 min. Finally, the slides were developed with 3,3'-diaminobenzidine and counterstained with haematoxylin and eosin. Cover slips were applied with gum and the slides were observed under a light microscope.
STATISTICAL ANALYSES
Statistical analyses were carried out using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Quantitative data were presented as mean ± SD. Student's t-test for two independent samples was performed for comparisons between two groups. Pearson's correlation B Wang, K Zuo, Y Wu et al. B lymphocytes unrelated to renal disease activity in IMN analysis (r) was performed for data with a normal distribution and Spearman's correlation analysis (ρ) for data with a nonnormal distribution. A P-value < 0.05 was considered to be statistically significant.
Results
STUDY POPULATION
A total of 66 patients with IMN were recruited into the study; 45 men and 21 women with an overall mean ± SD age of 49.2 ± 14.7 years (range 21 -62 years). A total of 40 healthy volunteers, 13 women and 27 men with an overall mean ± SD age of 45.7 ± 16.8 years (range 19 -65 years) formed the control group.
CHANGES IN PERIPHERAL BLOOD LYMPHOCYTES
Compared with healthy control subjects, the number of peripheral blood CD4 + CD25 + Foxp3 + regulatory T-cells was significantly reduced in IMN patients (P < 0.01) ( Table 1 , Fig. 1 ). In contrast, the amount of peripheral blood B lymphocytes in patients with IMN was significantly higher than in the healthy subjects (P < 0.01) ( Table  1 , Fig. 2 ). Compared with normal controls, the number of peripheral blood CD3 + and CD8 + T-cells in IMN patients was slightly reduced and that of CD4 + T-cells was slightly increased, although none of the differences was statistically significant ( Table 1) . The CD4 + /CD8 + T-cell ratio was significantly elevated in IMN patients compared with control subjects (P < 0.01) (Table 1, Fig. 3 ).
CORRELATION ANALYSES
In patients with IMN, correlation analysis indicated no relationship between the number of peripheral blood B lymphocytes and the amount of urine protein (r = 0.202), or between the number of peripheral blood B lymphocytes and the amount of serum albumin (r = -0.098). Correlation analysis was also performed in IMN patients with urine protein > 3.0 g/24 h; the results showed no relationship between the number of peripheral blood B lymphocytes and the amount of urine protein (r = 0.068), or between the number of peripheral blood B lymphocytes and amount of serum albumin (r = -0.135). Correlation analysis also indicated no relationship between the number of peripheral blood B lymphocytes and serum creatinine, a marker of renal function (r = 0.23), or between the number of peripheral blood B lymphocytes and NAG (r = 0.099) or RBP levels (ρ = 0.036), both markers of renal tubular function. 
B Wang, K Zuo, Y Wu et al. B lymphocytes unrelated to renal disease activity in IMN B LYMPHOCYTES IN THE KIDNEY OF IMN PATIENTS
Light microscopy of kidney samples was carried out to detect the density and distribution of infiltrating B lymphocytes. The mean ± SD number of infiltrating B lymphocytes was 40.0 ± 43.7 cells/mm 2 (range 8 -256 cells/mm 2 ) in the kidney of IMN patients, which was higher than that observed in healthy subjects (≤ 11 cells/mm 2 ). Scattered distribution and regional clustering of B lymphocytes were observed in the kidney of patients with IMN (Fig. 4 ). In the case of regional clustering, B lymphocytes were frequently found in the peritubular capillaries or around the renal glomeruli. The level of urine NAG in patients with regional clustering of B lymphocytes in the kidney was significantly higher than in patients without regional clustering (P = 0.05; Table 2 ). No significant differences were found in the levels of urinary protein, urinary RBP, serum creatinine or peripheral blood B lymphocytes between patients with regional clustering of B lymphocytes and those with scattered B lymphocytes ( Table 2 ). Correlation analysis demonstrated no relationship between the number of peripheral blood B lymphocytes and that of infiltrating B lymphocytes in the kidney of IMN patients (r = 0.23).
Discussion
It is now considered that IMN is an autoimmune disease mediated by antigenantibody interactions. 14 
B lymphocytes unrelated to renal disease activity in IMN
Humoural immunity is primarily mediated by B lymphocytes that recognize and present antigens, synthesize and secrete antibodies, and modulate immune responses, suggesting their critical role in the pathogenesis of autoimmune diseases. 18 The presence of CD20 protein is observed as early as the pre-B lymphocyte stage and it can be found at all stages of B lymphocyte development except for the plasma cell stage. 19, 20 Thus, CD20 is considered a unique marker for human B lymphocytes. CD20 mainly exerts effects on the proliferation and differentiation of B lymphocytes and plays an important role in regulation of the immune system. 21 Studies have indicated that IgG4 occurs in the epithelium of the kidney of IMN patients. 22, 23 Under the stimulation of interleukin-4 (IL-4) and IL-10 secreted by Th2 cells, IgG4 in B lymphocytes was up-regulated. 6 In addition, B lymphocytes are implicated in the development of renal injury as a result of their antigen-presenting role. 14 Although B lymphocytes play an important role in the pathogenesis of IMN, the various lymphocyte subsets are part of a complicated system with multiple interactions between different cell types. The B lymphocytes are not only regulated by regulatory T-cells, but they also interact with helper T-cells. 3 This leads to questions of: What roles do B lymphocytes play in the pathogenesis of membranous nephropathy? Could B lymphocytes be an effective target for the treatment of IMN?
To date, rituximab has been clinically applied in IMN and its effectiveness has been observed to a limited extent. 24, 25 These studies had small sample sizes and were not prospective randomized clinical trials. 24, 25 Of note, rituximab reduced the number of peripheral blood B lymphocytes in all IMN patients, but a fraction of patients did not have improved proteinuria. 16 What then is the explanation for the down-regulation or deficiency in the number of B lymphocytes while proteinuria remains unchanged? The number of B lymphocytes, lymphocyte subsets and regulatory T-cells was measured in the present study to explore the relationship between these parameters and the clinical manifestations of IMN, including proteinuria, renal function and renal tubular function.
The present study indicated that the number of B lymphocytes was significantly increased in IMN patients accompanied by a decreased number of regulatory T-cells and an elevated blood CD4 + /CD8 + T-cell ratio.
Regulatory T-cells confer negative regulatory effects on the immune response mediated by T-cells, and they can inhibit the proliferation of CD4 + T lymphocytes and the secretion of cytokines (mainly IL-2). 26 In addition, they may also suppress self-reactive T-cells (CD8 + ). 27 These functions of regulatory T-cells 28, 29 Previous studies have shown that the number of peripheral blood CD4 + CD25 + regulatory T-cells was markedly decreased in patients with autoimmune disease and was accompanied by impaired functions. 28, 30 Thus, enhanced proliferation and activity of B lymphocytes caused by regulatory T-cells may also be occurring in IMN patients, resulting in abnormal humoural and cell-mediated immunity, and leading to production of autoantibodies and the formation of an in situ immune complex.
Further analysis in the present study showed, however, that the number of peripheral blood B lymphocytes was not correlated with urine protein or serum albumin levels. To exclude the influence of an immune response during a stable phase of the disease on these parameters and to evaluate the relationship between the number of peripheral blood B lymphocytes and the amount of urine protein during an active phase, patients with severe proteinuria were selected for further analysis. The results demonstrated no relationship between the number of peripheral blood B lymphocytes and the amount of urine protein or serum albumin in patients with severe proteinuria. Furthermore, no correlation was found between the number of peripheral blood B lymphocytes and renal function (creatinine) or renal tubular function (NAG, RBP).
Previous studies have implied that the number of infiltrating B lymphocytes in the renal interstitium is related to the prognosis of IMN patients. 14, 31 Immunohistochemistry was used in the present study to investigate the distribution of infiltrating B lymphocytes in the kidney of IMN patients. 14 The results suggest that the number of infiltrating B lymphocytes in the renal interstitium was significantly increased, accompanied by focal aggregation of B lymphocytes. Moreover, the level of urinary NAG, a marker of renal tubular injury, was significantly elevated in the IMN patients with focal aggregation (clustering) of B lymphocytes compared with those patients without focal aggregation (scattering) of B lymphocytes. Interstitial injury of the renal tubules has been reported to be related to prognosis and therapeutic response of IMN patients, suggesting that focal aggregation of B lymphocytes in the renal interstitium might be beneficial for the determination of prognosis. 32 Further analysis showed no evident correlation between the number of B lymphocytes in the peripheral blood and the number in the renal interstitium.
Taken together, the present study showed abnormalities of B lymphocytes in IMN patients, and these might be associated with a reduced number and suppressed functions of regulatory T-cells. No direct correlations were observed between the number of peripheral blood B lymphocytes and urinary protein level or the severity of renal disease (renal function, renal tubular function and the number of infiltrating B lymphocytes in the renal interstitium) in IMN patients. The number of B lymphocytes was significantly increased in IMN patients, but this did not reflect the severity of IMN. Thus, the present study suggests that the number of peripheral blood B lymphocytes may not be a good marker of IMN disease activity and severity for the guidance of IMN treatment and measurement of its efficacy.
